Exploring new approaches to treat mesothelioma
New Preclinical and Clinical Approaches to Mesothelioma, an Archetypal Inflammatory Tumor
This study is trying to see if targeting certain proteins can help improve treatment and immune response for people with mesothelioma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Sex | All |
| Sponsor | IRCCS Ospedale San Raffaele Academic / other |
| Locations | 2 sites (Naples, Campania and 1 other locations) |
| Trial ID | NCT06536179 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the roles of HMGB1 and CXCR4 in mesothelioma treatment and metastasis. It involves collaboration between two major cancer research institutions in Italy, focusing on how targeting these pathways can inhibit tumor progression and enhance anti-tumor immunity. The study will collect additional blood samples during routine clinical practice to support its findings. By understanding these mechanisms, the research hopes to improve therapeutic outcomes for patients with mesothelioma.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a clinical suspicion or confirmed diagnosis of pleural mesothelioma who are candidates for surgical intervention.
Not a fit: Patients without pleural mesothelioma or those whose diagnosis does not confirm clinical suspicion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies that significantly improve treatment outcomes for mesothelioma patients.
How similar studies have performed: While targeting HMGB1 and CXCR4 in cancer treatment is a promising approach, the specific combination and methodology in this study may be novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Mesothelioma: Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma. * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. * Capacity to comprehend the study nature and provide autonomously informed consent. Control Group patients: * Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious). * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. * Ability to understand the study nature and provide autonomously informed consent. If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study. Exclusion Criteria: * Lack of biopsy material. * pregnancy. * Unwillingness to sign the Informed Consent.
Where this trial is running
Naples, Campania and 1 other locations
- Istituto Nazionale Tumori IRCCS Fondazione G.Pascale — Naples, Campania, Italy (Recruiting)
- IRCCS San Raffaele — Milan, Lombardy, Italy (Recruiting)
Study contacts
- Principal investigator: Marco Bianchi, Professor — IRCCS Ospedale San Raffaele
- Study coordinator: Massimo Crippa, PhD
- Email: crippa.massimo@hsr.it
- Phone: 02-26434833
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.